New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
07:08 EDTNNVCNanoViricides reports construction of new facility nearing completion
NanoViricides reported that construction of the modern R&D Lab and cGMP Clinical Production facility in Shelton, Connecticut, is nearing completion with some weather-related delays. The company reports that the R&D lab section of the facility is ahead of schedule. Once construction of the cGMP Clean Room Production Suite is completed, the project will enter the facility testing and validation phase. The company is performing certain scale-up studies and production of the quantities of FluCide needed for the “Tox Package” study at its current facility, as previously reported. The company anticipates transitioning staff to the new facility upon obtaining a Certificate of Occupancy. The total renovation project went through many changes of design and scope to fit the budget. Construction began in earnest around August 2013, as previously reported by the company. Though generally on schedule, the recent severe winter weather has delayed delivery of certain specialty equipment necessary for the cGMP Clean Room and has created some construction delays.
News For NNVC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
07:12 EDTNNVCNanoViricides signs agreement with University of Wisconsin
NanoViricides announced that it has entered into an agreement with the University of Wisconsin for the evaluation of its nanoviricides drug candidates in models of ocular herpes virus infections. The studies will be performed in the laboratory of Dr. Curtis Brandt, an expert in herpes simplex virus infections and in evaluating anti-viral agents. The Company has previously reported the successes of its nanoviricides drug candidates in pre-clinical studies of dermal herpes virus infections in mouse models. The studies in Dr. Brandt's laboratory will be critical in optimizing its anti-herpes drug candidates against ocular herpes virus infections. The goal of these studies will be to identify a drug development candidate as a treatment for ocular keratitis in humans caused by herpes simplex virus infections.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use